0.83 +0.03 (3.75%)
After hours: 5:51PM EDT
|Bid||0.81 x 5000|
|Ask||0.83 x 3300|
|Day's Range||0.76 - 0.82|
|52 Week Range||0.76 - 1.47|
|PE Ratio (TTM)||2.58|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to VIVUS, Inc. Here are 5 ETFs with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis VIVUS, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 11.23 million, Net Earnings of USD -13.39 million. Gross margins narrowed from 80.79% to 68.20% compared to the same period last year, operating (EBITDA) margins now -42.20% from -24.58%. Change in operating cash ... Read more (Read more...)
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.
VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.
Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.
Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.
Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.
KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.
Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.
Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.
Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older